Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2015 Jul 23;14(10):2249–2259. doi: 10.1158/1535-7163.MCT-15-0429

Figure 2. Investigation of CGM097 against primary AML patient cells expressing either wt or mutant p53.

Figure 2

CGM097 treatment of primary AML patient samples (A) or normal bone marrow samples (B). MOLM-13 (wt p53-expressing) and KU812F (mutant p53-expressing) are shown as controls for (A) and MOLM14 (wt p53-expressing) is shown as a control for (B). Results shown are following approximately 2–3 days of treatment. Differences in CGM097 responses in wt p53-expressing AML and mutant p53-expressing AML samples were significant as determined by Student’s t-test (p=0.010964621). (C) Yeast-based p53 functional assay. 1&2:AML patient sample #1 (wt p53); 3&4: pRDI-22 plasmid only; 5: OCI-AML3 (wt p53); 6,7,8,&9: KU812F (mutant p53); 10: OCI-AML5 (wt p53); 11&12: AML patient sample #2 (wt p53).